Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Proactively manage your pharmacy inventory
Manage your formulary budget
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Extended release form of diltiazem|
|Abstract:||An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.|
|Inventor(s):||Deboeck; Arthur M. (Gurabo, PR), Baudier; Philippe R. (Waterloo, BE)|
|Assignee:||Galephar P.R., Inc., Ltd. (Carolina, PR)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Germany||69229949||<disabled in preview>|
|Canada||2111085||<disabled in preview>|
|Australia||2243092||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.